Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers June 23, 2017
Pharmacy Choice - Pharmaceutical News - Dr. Reddy's To Launch Generic Version Of Doxil - June 23, 2017

Pharmacy News Article

 5/17/17 - Dr. Reddy's To Launch Generic Version Of Doxil

NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (RDY) announced it has received approval from the U.S. FDA to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil (doxorubicin hydrochloride liposome injection), for intravenous use, in the U.S. market.

The Doxil brand and generic had U.S. sales of approximately $196 million MAT for the most recent twelve months ending in March 2017. DOXIL is a registered trademark of ALZA Corp.

Dr. Reddy's Laboratories stated that the FDA approval is an outcome of extensive collaboration with the company's partner, Natco Pharma Ltd. on R&D and manufacturing capabilities.

Copyright RTT News/dpa-AFX

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Jun 25: Legal & Practical Issues in Compounding Pharmacy
Jun 26: Drug Diversion & the Law: Considerations for Pharmacists & Technicians
Jun 27: Medication Adherence: To Take or Not to Take…That is the Problem
Jun 28: Mobile Applications for Pharmacists: Tools That Help Pharmacies be Successful
Jun 29: REMS Drugs & The Practice of Pharmacy: A Program in Law and Risk Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement